Request Trial
formatoriginal-regeneron
Formatoriginal / Shutterstock.com
28 October 2021Alex Baldwin

Regeneron convinces PTAB to review Novartis syringe patent

The  US Patent Trial and Appeal Board (PTAB) has granted a review of a Novartis syringe patent following a challenge from biotech giant  Regeneron.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Careers
Cooley Asia transactions duo make rival firm move
23 June 2026   The pair bring a strong track record advising life sciences companies on licensing, collaboration and commercialisation agreements, with a particular focus on cross-border biotech transactions.
Biotechnology
Insilico lands potential $2.5bn AI biotech partnership
22 June 2026   The partnership, announced at BIO 2026, marks the largest Asia-Pacific partnership by potential value that the AI-driven drug discovery company has secured to date.
Asia
‘Blatant imitation’: Indian court blocks copycat pharma branding
22 June 2026   The court granted Blue Cross Laboratories a permanent injunction after finding that a rival product’s mark and packaging closely mirrored its own.


Editor's picks

Hikma v Amarin: Six takeaways from the pivotal ruling
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026

Editor's picks

Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026
Americas
UK govt backs DeepMind spinout’s $2.1bn plan to ‘solve all disease’ with AI
14 May 2026
Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026
Americas
Penile implant maker’s $17m trade secret award unravels
20 April 2026
Biotechnology
Closing the women's health gap offers ‘benefits for all’
7 April 2026
Europe
European patent offices raise fees
2 April 2026

More features

Cooley Asia transactions duo make rival firm move
Insilico lands potential $2.5bn AI biotech partnership
‘Blatant imitation’: Indian court blocks copycat pharma branding
UPC hands Occlutech second win against Chinese medtech company in a month
US life sciences damages averaged $33.5m between 2019-2025
Quantum and photonics tech licensing expert joins EIP
Court upholds $83m sequencing verdict and sets royalty rate
Exclusive: ‘Cultural differences are an asset’ at the UPC